From Day 8 subjects will begin a combination period consisting of treatment with SC BL-8040 (1.25 mg/kg) three times a week (TIW) and pembrolizumab (200mg) once every three weeks. The combination therapy will continue for up to two years, or until progression, clinical deterioration or early termination, whichever comes first.